Posted by Michael Wonder on 15 Dec 2020
U.S. FDA accepts new drug application for review, grants priority review for Takeda’s TAK-721 (budesonide oral suspension) for the treatment of eosinophilic oesophagitis
15 December 2020 - If approved, TAK-721 will be the first FDA approved treatment for the chronic inflammatory disease; Takeda plans to use the trade name Eohilia (budesonide oral suspension).
Takeda today announced that the United States FDA has accepted for review the company’s new drug application and granted priority review for the investigational therapy budesonide oral suspension, TAK-721, which has been designed specifically for eosinophilic oesophagitis.
